A two-stage genome-wide association study identifies novel germline genetic variations in CACNA2D3 associated with radiotherapy response in nasopharyngeal carcinoma

Table 1 Characteristics of all patients

Characteristics	Discovery stage	Validation stage 1	Validation stage 2
Number of patients	319	662	185
Age (Mean ± SD)	50.75 ± 11.96	47.45 ± 10.49	51.26 ± 12.13
Gender
Male	215	488	131
Female	104	173	54
BMI (Mean ± SD)	22.61 ± 3.40	23.18 ± 3.26	23.53 ± 3.27
Smoking status
Smoker	151	320	74
Non–smoker	168	334	17
NR	0	7	94
Drinking status
Drinker	72	227	35
Non–drinker	247	427	21
NR	0	7	129
Clinical stage
I	7	41	1
II	26	55	12
III	120	302	93
IV	165	258	79
NR	1	5	0
EBV
Positive	216	436	90
Negative	103	219	95
NR	0	6	0
Treatment
RT alone	60	12	20
RT + IC/AC	4	39	19
CCRT	100	23	23
CCRT + IC/AC	154	551	123
RT + other treatment*	1	36	0

SD Standard deviation, BMI Body mass index, EBV Epstein-Barr virus, NR Not reported, RT Radiotherapy, IC Induction chemotherapy, AC adjuvant chemotherapy, CCRT Concurrent chemoradiotherapy
*Other treatment included surgery, targeted therapy, immunotherapy and herbs treatment

ISSN: 1479-5876